NASDAQ · CGTX
Cognition Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CGTX: Nov 5, 2026
Cognition Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.07 | $-0.06 | $-0.07 | 3 |
| Dec 2026 | $-0.14 | $-0.05 | $-0.26 | 3 |
| Mar 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Jun 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · BNK Invest- Fintel · Oct 22, 7:13 AM EDTCognition Therapeutics, Inc. Aligns with FDA on Pivotal Phase 3 Trial of Zervimesine in Dementia with Lewy BodiesCognition Therapeutics, Inc. has aligned with the U.S. Food and Drug Administration on key elements of a Phase 3 study in dementia with Lewy bodies including patient selection, dose, duration, and endpoints. The planned registrational study is expected to enroll participants with
- RTTNews · Oct 22, 6:47 AM EDTCognition Aligns With FDA On Pivotal Phase 3 Study For Dementia With Lewy Bodies; Stock Up(RTTNews) – Cognition Therapeutics (CGTX) announced that it has aligned with the U.S. FDA on key aspects of a planned Phase 3 study evaluating zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB), paving the way for a potential registrational trial.
- RTTNews · Sep 29, 6:17 PM EDTCognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug Zervimesine(RTTNews) – Cognition Therapeutics Inc. (CGTX), a clinical-stage biopharmaceutical company, on Tuesday reported the upcoming Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology regarding a planned Phase 3 registrational study of Zervimesine in tr
- RTTNews · Aug 7, 2:09 AM EDTCognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027(RTTNews) – Cognition Therapeutics, Inc. (CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, reported second quarter results reflecting a narrowed net loss and provided a business update.
- Zacks · Aug 6, 7:10 PM EDTCognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue EstimatesCognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 24, 9:04 AM EDTCognition Seures FDA Alignment For Pivotal Phase 3 Trial Of Zervimesine In DLB Psychosis(RTTNews) – Cognition Therapeutics, Inc. (CGTX) announced that it has reached key alignment with the U.S. FDA on the design of its pivotal Phase 3 study evaluating Zervimesine for psychosis associated with dementia with Lewy bodies (DLB), marking a major regulatory milestone for
- BNK Invest · Mar 31, 12:01 PM EDTTuesday Sector Leaders: Precious Metals, DrugsIn trading on Tuesday, precious metals shares were relative leaders, up on the day by about 6.2%. Leading the group were shares of TRX Gold, up about 11.9% and shares of Hycroft Mining Holding up about 11.6% on the day. Also showing relative strength are drugs shares, up on th
- NASDAQ.com · Mar 25, 4:00 PM EDTPre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTIThe following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Commercial Metals Company (CMC)is reporting for the quarter ending February 28, 2026. The steel company's consens
- RTTNews · Dec 16, 11:29 PM ESTAfter-Hours Gainers: A Quiet Session With A Standout Biotech Surge(RTTNews) – The after-hours market delivered a mixed but generally positive tone on Tuesday evening, with several small- and mid-cap names posting modest gains. One biotech, however, stole the spotlight with a dramatic surge following major clinical news.
- Fintel · Dec 4, 7:02 AM ESTHC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy RecommendationFintel reports that on December 4, 2025, HC Wainwright & Co. reiterated coverage of Cognition Therapeutics (NasdaqCM:CGTX) with a Buy recommendation. Analyst Price Forecast Suggests 84.17% Upside
- RTTNews · Nov 25, 11:30 PM ESTBiotech And Healthcare Names Lead After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO(RTTNews) – Several small- and mid-cap biotech and healthcare names posted notable gains in Tuesday's after-hours trading, with investor attention drawn to corporate updates and recent financing developments.
- Fintel · Nov 21, 7:03 PM ESTB. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy RecommendationFintel reports that on November 21, 2025, B. Riley Securities reiterated coverage of Cognition Therapeutics (NasdaqCM:CGTX) with a Buy recommendation. Analyst Price Forecast Suggests 149.25% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cognition Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.